<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nine patients with advanced stages of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received aggressive chemotherapy with high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> or with a standard <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid leukemic regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Six of them were in frank <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid leukemic phase </plain></SENT>
<SENT sid="2" pm="."><plain>The mean age was 57 years (range 32-71) </plain></SENT>
<SENT sid="3" pm="."><plain>Seven patients obtained remission, 6 complete remission (CR) and 1 partial remission </plain></SENT>
<SENT sid="4" pm="."><plain>The induction remission rate was 77.7% </plain></SENT>
<SENT sid="5" pm="."><plain>There were 2 <z:hpo ids='HP_0011420'>deaths</z:hpo> in the <z:mpath ids='MPATH_58'>aplasia</z:mpath> period because of infectious complications </plain></SENT>
<SENT sid="6" pm="."><plain>The mean duration <z:mpath ids='MPATH_58'>aplasia</z:mpath> was 36 days (range 21-69) </plain></SENT>
<SENT sid="7" pm="."><plain>In spite of this <z:hpo ids='HP_0000001'>all</z:hpo> responders received further consolidation chemotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>The mean duration of CR was 10 months </plain></SENT>
<SENT sid="9" pm="."><plain>We concluded that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with excess of blasts and blastic transformation may be treated with aggressive chemotherapy with low toxicity and high remission rate, similarly to de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
</text></document>